Gordon (Roy) Davis – Chair of the Nominations Committee and Member of the Remuneration Committee
Roy has extensive experience spanning medical devices, diagnostics, and the digital healthcare space. He is currently Chairman of Foster & Freeman, a leading forensic imaging manufacturer, Non-Executive Chair (Designate) at Inspiration Health and Non-Executive Director at Futura Medical.
Prior to these roles, Roy served Chairman of Medica Company PLC and chief executive officer of Optos plc, a leading ophthalmology medical device business, from 2008 until June 2016 when he stepped down following the company’s acquisition by Nikon Corporation.
Before joining Optos, he served from 2007 as chief executive officer of Gyrus Group plc, a leading medical device company, prior to its acquisition by the Olympus Corporation of Japan in 2008, having previously served as COO of Gyrus from 2003 and a Non-Executive Director since its IPO in 1997.
Prior to this, Roy was the CEO of NTERA, a nanotechnology company, and before that spent almost ten years with Arthur D Little, the global management consulting company, where he was Vice President and Global Head of its operations management business.
Andrew Boteler – Chair of the Remuneration and Audit Committee and Member of the Nominations Committee
Andrew is a UK qualified chartered accountant and currently Non-Executive Director of Octopus AIM VCT plc. From 2019 to 2023 Andrew was CFO Finance Director of Riverford Organic Farmers Limited and from 2009 to 2019, Andrew was CFO of Gooch & Housego PLC and in addition, was responsible for legal, investor relations and IT. He has had over 25 years working in the manufacturing sector, spending 19 of those years with high technology manufacturing companies. Andrew is experienced in M&A and fund raising, including management buy-out, trade sales and bank funding.
James McCullough – Member of the Remuneration, Audit and Nominations Committee
James McCullough is the CEO of Renalytix AI (AIM:RENX, NASDAQ:RNLX) and has experience building emerging technology companies in both the public and private sectors with specific expertise in the life-sciences industry.
Prior to his role at Renalytix AI, James served as CEO of Exosome Diagnostics, a venture capital backed personalized medicine company developing noninvasive liquid biopsy diagnostics in cancer, which was acquired by Bio-Techne in 2018. He is a managing partner at Renwick Capital, LLC and also serves on the board of directors of Verici Dx Plc, Kantaro Biosciences and the GO2 Foundation for Lung Cancer. James has served as a board Director for LungLife AI since 2019.
Sara Barrington – Member of the Remuneration Committee
Sara is CEO of Verici Dx (AIM:VRCI) and CCO of Kantaro Biosciences, LLC. Sara previously served as CEO of the Company from January 2019 to May 2020. She has held numerous senior roles including EVP of Business Operations with Bruin Biometrics, CFO of Exosome Diagnostics, and CFO at AusAm Biotechnologies. Prior to working in the US, she worked for British Telecom in London in business development and strategy.
Sara is qualified as a Chartered Accountant with the Institute of Chartered Accountants in England and Wales. She has also qualified with Chartered Institute of Marketing.
LungLife AI licensure/accreditation information posted here.